Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT

被引:51
作者
Alssema, Marjan [1 ,2 ,3 ]
Rijkelijkhuizen, Josina M. [1 ,2 ]
Holst, Jens J. [4 ]
Teerlink, Tom [5 ]
Scheffer, Peter G. [5 ]
Eekhoff, Elisabeth M. W. [5 ]
Gastaldelli, Amalia [6 ]
Mari, Andrea [7 ]
Hart, Leen M't [8 ]
Nijpels, Giel [2 ,9 ]
Dekker, Jacqueline M. [1 ,2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands
[3] Unilever Res Labs, NL-3133 AT Vlaardingen, Netherlands
[4] Univ Copenhagen, NovoNordisk Fdn Ctr Basic Metab Res, Panum Inst, Dept Biomed Sci, Copenhagen, Denmark
[5] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[6] CNR, Inst Clin Physiol, I-56100 Pisa, Italy
[7] CNR, Inst Biomed Engn, Padua, Italy
[8] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands
[9] Vrije Univ Amsterdam Med Ctr, Dept Gen Practice, Amsterdam, Netherlands
关键词
GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; ORAL GLUCOSE; INSULIN SENSITIVITY; INCRETIN HORMONES; HEALTHY-SUBJECTS; MELLITUS; OBESITY;
D O I
10.1530/EJE-13-0487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To i) compare incretin responses to oral glucose and mixed meal of diabetic patients with the normoglycaemic population and ii) to investigate whether incretin responses are associated with hypertriglyceridaemia and alanine aminotransferase (ALT) as liver fat marker. Design: A population-based study. Methods: A total of 163 persons with normal glucose metabolism (NGM), 20 with intermediate hyperglycaemia and 20 with type 2 diabetes aged 40-65 years participated. Participants received a mixed meal and oral glucose load on separate occasions. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon profiles were analysed as total area under the curve (tAUC) and incremental area under the curve. Results: In diabetic patients compared with persons with NGM, we found increased GLP-1 secretion (tAUC per hour) following oral glucose (23.2 pmol/l (95% CI 17.7-28.7) vs 18.0 (95% CI 16.9-19.1), P < 0.05) but not after the mixed meal. GIP secretion among diabetic patients was increased on both occasions (82.9 pmol/l (55.9-109.8) vs 47.1 (43.8-50.4) for oral glucose and 130.6 (92.5-168.7) vs 83.2 (77.5-88.9) for mixed meal, both P < 0.05). After oral glucose, GLP-1 (tAUC per hour) was inversely related to fasting triglycerides. GIP (tAUC per hour) was positively related to fasting and postprandial triglycerides. Higher fasting GIP levels were related to higher fasting and postprandial triglyceride levels and ALT. Conclusion: This study confirms that in type 2 diabetes, GLP-1 secretion is generally preserved and that GIP secretion is exaggerated. The mechanism underlying the divergent associations of GLP-1 and GIP metabolism with fat metabolism and liver fat accumulation warrants further study.
引用
收藏
页码:421 / 430
页数:10
相关论文
共 48 条
[1]   Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance [J].
Ahren, B ;
Larsson, H ;
Holst, JJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (02) :127-131
[2]  
[Anonymous], INT J OBESITY
[3]  
[Anonymous], 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation
[4]   Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men [J].
Brons, Charlotte ;
Jensen, Christine B. ;
Storgaard, Heidi ;
Hiscock, Natalie J. ;
White, Andrew ;
Appel, Julie S. ;
Jacobsen, Stine ;
Nilsson, Emma ;
Larsen, Claus M. ;
Astrup, Arne ;
Quistorff, Bjorn ;
Vaag, Allan .
JOURNAL OF PHYSIOLOGY-LONDON, 2009, 587 (10) :2387-2397
[5]   Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies [J].
Calanna, S. ;
Christensen, M. ;
Holst, J. J. ;
Laferrere, B. ;
Gluud, L. L. ;
Vilsboll, T. ;
Knop, F. K. .
DIABETOLOGIA, 2013, 56 (05) :965-972
[6]   New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser [J].
Cho, Y. M. ;
Kieffer, T. J. .
DIABETOLOGIA, 2011, 54 (02) :219-222
[7]  
Clements RH, 2004, AM SURGEON, V70, P1
[8]   Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes [J].
Courreges, J. -P. ;
Vilsboll, T. ;
Zdravkovic, M. ;
Le-Thi, T. ;
Krarup, T. ;
Schmitz, O. ;
Verhoeven, R. ;
Buganova, I. ;
Madsbad, S. .
DIABETIC MEDICINE, 2008, 25 (09) :1129-1131
[9]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[10]   What do we know about the secretion and degradation of incretin hormones? [J].
Deacon, CF .
REGULATORY PEPTIDES, 2005, 128 (02) :117-124